

ACT-AD

Accelerate Cure/Treatments for Alzheimer's Disease

12th Annual FDA/Alzheimer's Disease Allies Meeting

*Diversifying the Therapeutic Pipeline for Alzheimer's Disease:
From Targets to Trials*

The Bethesdan Hotel
8120 Wisconsin Avenue, Bethesda, MD 20814
November 13, 2019
Room Bethesdan CD-2nd Floor | 9:00 am – 4:30 pm

OBJECTIVES

The Accelerate Cure/Treatments for Alzheimer's Disease (ACT-AD) Coalition's 12th annual meeting will explore the current therapeutic landscape for AD from discovery and validation of novel targets through clinical testing of novel drug candidates and non-pharmacologic interventions. The meeting will also provide a forum for receiving updates on the National Institutes of Health's investments in a precision medicine approach to the development of Alzheimer's disease treatment and prevention. A series of expert presentations will be followed by robust discussion with the leadership of the National Institute on Aging, CMS, and the FDA's Division of Neurology Products. These discussions will help to assist the field in more rapidly deploying knowledge to develop and deliver effective pharmacologic and non-pharmacologic therapeutic approaches for AD.

WELCOME

9:00-9:30 a.m. **Registration and Breakfast**

9:30-9:45 a.m. **Welcome and Introductions**

PRESENTATIONS

9:45-9:55 a.m. **Next Steps for Aducanumab**
Samantha Budd Haeberlein, Biogen

9:55-10:05 a.m. **Discussion**

10:05-10:15 a.m. **China's Conditional Approval of Oligomannate**
TBD

10:15-10:25 a.m. **Discussion**

10:25-10:45 a.m. **Expanding the Therapeutic Target Landscape for AD:
AMP-AD Target Discovery Program and AD Centers for New
Medicines**
Suzana Petanceska, Ph.D., National Institute on Aging

10:45-11:05 a.m. **Discussion**

- 11:05-11:25 a.m. **Understanding the Role of Viruses in AD: Implications for New Therapeutics and Diagnostics**
Ben Readhead – Arizona State University
- 11:25-11:45 a.m. **Discussion**
- 11:45-12:05 p.m. **Systems Genetics Approach to Discover and Validate Resilience-Based Therapeutic Targets for AD prevention**
Catherine Kaczorowski, Jackson Labs
- 12:05-12:25 p.m. **Discussion**
- 12:25-1:00 p.m. **Lunch**
- 1:00-1:20 p.m. **Developing Translational Tools, Drugs and Companion Diagnostics to Target the Dysregulated Chaperome in Alzheimer’s Disease**
Gabriela Chiosis – Memorial Sloan Kettering Cancer Center
- 1:20-1:40 p.m. **Discussion**
- 1:40-2:00 p.m. **Treating the Whole Patient - NIA’s Clinical Trials Pipeline:**
Laurie Ryan, National Institute on Aging
- 2:00-2:20 p.m. **Discussion**
- 2:20-2:40 p.m. **Targeting Modifiable Risk Factors for AD treatment and Prevention**
Laura Baker – Wake Forest Medical School
- 2:40-3:00 p.m. **Discussion**
- 3:00-3:20 p.m. **Preclinical and Clinical Development of Neurotrophin Receptor Modulators for AD Treatment**
Frank Longo – Pharmatrophix
- 3:20-3:40 p.m. **Discussion**
- 3:40-4:00 p.m. **Advancing PDE4 Allosteric Inhibitors as Symptomatic and Disease Modifying Treatment for AD**
Mark Gurney – Tetra Therapeutics
- 4:00-4:20 p.m. **Discussion**
- CLOSING**
- 4:20-4:30 p.m. **Summary and Concluding Remarks**